News Hub | News Direct

All Industries


Article thumbnail News Release

PathAI Collaborates with GoldPath to Elevate Digital Pathology Capabilities with AISight Image Management System

PathAI

PathAI, a global leader in digital pathology, announced today that GoldPath, an independent pathology service provider based in Duarte, California, has adopted the AISight Ⓡ1 Image Management System (IMS). In a competitive and evolving pathology landscape, where the demand for accurate and timely diagnostics is ever-increasing, the integration of digital pathology is becoming a critical differentiator for independent laboratories. GoldPath selected AISight after an extensive evaluation of various image management systems, recognizing it as the optimal solution to streamline workflows, enhance case management, and support a broad range of use cases. Through adopting AISight, GoldPath aims to reduce turnaround times for referring physicians and deliver cutting-edge pathology services. "As we continue to see a growing need for high-quality pathology services, integrating digital pathology is essential to maintaining our competitive edge and ensuring the best patient outcomes. AISight stood out for its robust capabilities, offering the versatility we need to manage our caseload effectively and improve efficiencies throughout our processes," said Gerardo De La O, CEO and Co-Founder of GoldPath. "The selection of PathAI's AISight Image Management System by a forward-thinking independent laboratory like GoldPath highlights the significant impact our technology can have on pathology operations. Their adoption of AISight demonstrates how our solution can enhance laboratory efficiency in the rapidly evolving field of digital pathology," said Andy Beck, MD, PhD, co-founder and CEO of PathAI. "We are excited to support GoldPath as they set new standards for pathology services." AISight, a cloud-native enterprise workflow solution, is central to PathAI's mission of revolutionizing the digital pathology ecosystem. Trusted by pathologists worldwide, AISight offers a comprehensive platform for case management, workload balancing, and image management, providing GoldPath with tools to address a wide array of histopathology use cases with exceptional versatility and efficiency. About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, please visit www.pathai.com. About GoldPath GoldPath is an independent, fully accredited pathology laboratory in “the City of Health” Duarte, California, dedicated to providing exceptional patient care, cutting-edge technology, and outstanding customer service. With a highly trained team of medical professionals and client relations specialists, GoldPath offers fast, accurate, and personalized laboratory services and a full range of ancillary support and practice management solutions. Footnote 1:AISight is for research use only. Not for use in diagnostic procedures. Contact Details SVM Public Relations and Marketing Communications +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

September 03, 2024 10:00 AM Eastern Daylight Time

Article thumbnail News Release

BitFuFu Posts 70% Revenue Growth And Outlines Strategic Expansion – Company Expects Continued Growth Amid Market Volatility

Benzinga

By Meg Flippin, Benzinga Volatility goes hand-in-hand with Bitcoin, particularly recently after the April halving. That rollercoaster ride isn’t for the faint-hearted or for many crypto companies. But it does seem to be for BitFuFu (NASDAQ: FUFU), the digital asset mining company based in Singapore. The company reports that it has created a sustainable business model, which performs well in both bullish and bearish market conditions due to its unique approach. This was recently on display, with BitFuFu reporting 69.7% year-over-year revenue growth in its second-quarter results and forecasting continued growth in the second half of 2024. “Our business model’s inherent flexibility – whether by increasing or reducing purchases of computing power, matching short-term and long-term procurements, or optimizing the mix between cloud-mining and self-mining computing power – enables us to sustain growth and profitability in a complex and volatile market environment,” said Leo Lu, BitFuFu’s Chairman and Chief Executive Officer, during the company’s earnings conference call. “Considering that total revenue of $273.8 million in the first half of 2024 nearly matches our full-year revenue for 2023, and with combined Q1 and Q2 adjusted EBITDA reaching $58.2 million, we expect substantial growth in both revenue and adjusted EBITDA in 2024, compared to 2023.” Checkout BitFuFu’s recent earnings report here! Outshining Some Rivals For the second quarter, BitFuFu posted revenue of $129.4 million, up almost 69.7% year-over-year. Growth was driven by strength in both its cloud-mining and self-mining operations. Cloud-mining revenue was up 66.8% compared to last year’s second quarter, with registered users increasing 86.8% to more than 395,000. Meanwhile, revenue in the company’s self-mining operations increased 81.0% to $51.1 million. Recurring revenue from customers active during the same period last year accounted for $47.4 million, or approximately 61.5% of cloud-mining revenue. New customers contributed $29.6 million, or 38.5%, highlighting the effectiveness of BitFuFu’s marketing and customer acquisition efforts. Notably, sales and marketing expenses as a percentage of cloud-mining revenue remained stable at 0.8%, demonstrating BitFuFu’s ability to scale and acquire users efficiently. Double-digit revenue growth isn’t new in the mining industry but BitFuFu’s approach is making it stand out from its rivals which include Bitfarms Ltd. (NASDAQ: BITF) and Riot Platforms Inc. (NASDAQ: RIOT). BitFuFu’s competitive advantage lies in its unique strategy of dynamically allocating hash rate between cloud-mining and self-mining, unlike its peers focused primarily on self-mining. This approach allows BitFuFu to generate upfront capital, scale operations, and hedge against Bitcoin price volatility by pre-selling hash rate at fixed prices. By securing future revenue regardless of market conditions, BitFuFu ensures resilience and profitability, distinguishing itself in both rising and declining markets. Cushioning the Potential Blow This strong growth is encouraging, given the April Bitcoin halving, which cut miners’ rewards by half, and a recent decline in Bitcoin prices that has many investors concerned. BitFuFu’s Lu acknowledged these challenges and highlighted the steps the company is taking to cut costs and improve profit margins if Bitcoin prices stay depressed. Since April, BitFuFu has applied technology to overclock the hashrate of its ASIC mining machines. For air-cooled machines, overclocking can increase computing power by 10% to 30% over the theoretical mining capacity of a mining machine. BitFuFu’s in-house mining facility management system has enhanced the efficiency of its mining machines, including those leased or operated by its partners. Additionally, BitFuFu has adjusted the operating mode of its mining machines in facilities with higher electricity and hosting fees and implemented a floating price mechanism in its hosting contracts. This approach allows the company to align costs with Bitcoin price fluctuations, reducing expenses and ensuring profitability even during downturns. BitFuFu is also actively acquiring mining facilities globally that offer lower electricity costs. BitFuFu is confident it will have news on that front soon, said Lu. The company is not just surviving in the current environment; it’s strategically positioning itself for future growth when Bitcoin prices rise again. BitFuFu remains confident in the long-term potential of Bitcoin, noting that year-to-date, Bitcoin’s price is up more than 40%, outperforming the S&P 500. “Given our long-term bullish outlook on Bitcoin, we are taking advantage of the current downturn in Bitcoin pricing to secure lower cost, long-term computing power,” said Lu. “Specifically, we intend to sign a two-year purchase agreement for computing capacity, enabling us to lock in a portion of our mining costs over the next two years.” Looking Beyond As BitFuFu scales, it is also building new revenue streams and growth opportunities. The mining facility management system, for example, has the potential to be monetized by offering it as a service to other miners. Additionally, BitFuFu is moving forward with its strategy to acquire or build its own mining farms. This vertical integration will allow BitFuFu to transition toward a more diversified and resilient portfolio of Bitcoin mining sites, including both self-owned/operated and third-party hosted sites. This strategy also enables further optimization of costs, particularly in terms of power consumption. Looking ahead, BitFuFu is also exploring synergies between mining and AI/HPC (High-Performance Computing) data centers. Both industries share a need for computational power, and expanding into AI/HPC could diversify BitFuFu’s revenue streams even further, reducing the impact of Bitcoin price volatility. The company is carefully evaluating opportunities in this space, recognizing the significant capital requirements involved. “BitFuFu had a strong second quarter and is well positioned for continued growth in the second half of 2024,” said Lu. “We remain focused on our strategy to increase our mining capacity while also improving fleet efficiency to grow revenue and profitability and drive long-term shareholder value.” Featured photo courtesy of BitFuFu. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 03, 2024 09:05 AM Eastern Daylight Time

Image
Article thumbnail News Release

Mariner Acquires Woodbridge International, Enhances M&A Advisory Capabilities

Mariner

Mariner, a national wealth advisory firm, today announced its acquisition of New Haven, Conn.-based Woodbridge International, a leading middle-market mergers and acquisitions firm. This acquisition significantly bolsters Mariner’s position as a comprehensive financial advisory firm, deepening its expertise in sell-side M&A advisory services. Woodbridge, which is known for its innovative approach to sell-side M&A transactions and its extensive experience across a wide range of industries, brings over 30 years of expertise and a team of seasoned professionals to Mariner. The acquisition will enable Mariner to offer enhanced M&A advisory services to its clients, leveraging Woodbridge’s global reach and industry-specific knowledge. “The integration of Woodbridge International into the Mariner family marks a transformative step in our mission to deliver comprehensive, client-focused financial services,” said Marty Bicknell, CEO and president of Mariner. “Woodbridge’s impressive history of successful transactions and its commitment to client-centric solutions align seamlessly with our core values. This acquisition enables us to broaden our service offerings, empowering our clients to navigate the complexities of M&A with greater confidence and precision.” Woodbridge has built a reputation for delivering exceptional results for its clients, focusing on maximizing value through innovative marketing strategies and a deep understanding of market dynamics. With offices in New Haven, CT and Cape Town, South Africa, Woodbridge is equipped with a global database of 8,400 private equity groups and 410,000 strategic companies. Woodbridge casts one of the widest nets in the industry, quickly identifying the greatest number of buyers. "For our team, joining forces with Mariner opens up incredible avenues for growth," said Robert Koenig, CEO of Woodbridge International. "We now have a clear path to potentially double our business within the next few years. By expanding our offerings, we can cultivate idle leads and provide more value to clients than ever before. This is an exciting time for Woodbridge, especially as we aim to capture the anticipated wave of baby boomer business exits." Both Mariner and Woodbridge are united by a shared commitment to making a meaningful impact on the clients they serve. This cultural alignment is at the heart of the acquisition, enabling Mariner to enhance its service offerings at a time when 35% of financial advisors are expected to retire over the next decade and $17 trillion in small businesses are projected to be sold in the next 20 years. This acquisition strengthens Mariner’s ability to support its 1,200 business owner clients, particularly during key business transitions. The acquisition was finalized on August 30, 2024, and the integration of Woodbridge’s team and operations into Mariner’s existing structure is expected to be completed by the end of the year. Woodbridge International will maintain its current offices and continue to operate under its established brand for a period of time, ensuring continuity for its clients and employees. To learn more, visit Mariner.com. Mariner is a privately held, national financial services firm equipped with the expertise to help meet the wealth needs of our clients. Our advisors have access to in-house professionals covering everything from tax, estate, trust and insurance to investment banking and valuation, so they can maximize time spent creating unified wealth plans with clients. By opening more windows of wealth, we create opportunities to positively impact the lives of many. With this purpose, we intend to raise the bar for the entire industry. Founded in 2006 with $300 million in assets under advisement, Mariner and its affiliates now advise on over $245 billion in assets as of 6/30/24. Contact Details Remi Yuter mariner@hotpaperlantern.com Company Website https://www.mariner.com/

September 03, 2024 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Early Cancer Detection Saves Lives - This Biotech Has A Promising New Test

Benzinga

By Johnny Rice, Benzinga Bill Caragol, CFO of Mainz BioMed (NASDAQ: MYNZ), was recently a guest on Benzinga’s All-Access. Mainz BioMed, maker of clinical laboratory tests, says it is committed to saving lives and reducing healthcare costs through early disease detection and prevention. For cancer and chronic conditions, patients can now live longer, healthier lives thanks to advances in diagnostic technology. Genetic and genomic tests are at the forefront of this progress. By revealing patients' unique genetic profiles, these tests can allow doctors to tailor treatments more effectively, ushering in an era of personalized medicine. Caragol spoke about promising data from recent trials. Watch the full interview here: Featured photo by National Cancer Institute on Unsplash Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 03, 2024 09:00 AM Eastern Daylight Time

Video Image
Article thumbnail News Release

How Dunamis Charge Is Helping Shape The Future Of EV Charging Infrastructure Through Its Wide Range Of American-Made High-Tech Solutions

Benzinga

By Meg Flippin, Benzinga Image: Dunamis Charge Level 2 EV Residential Charger In the rapidly evolving landscape of electric vehicles (EVs), Dunamis Charge aims to stand out as an innovator. As the EV market takes off, projected to reach $1.6 trillion by 2034, Dunamis Charge wants to be at the forefront of the charging infrastructure revolution with its charging solutions. After all, for the EV market to take off, there must be a level playing field where everyone can own an EV regardless of where they live or how much money they have. For that to happen, there needs to be robust, affordable and easy-to-use charging infrastructure that’s accessible everywhere. That’s what Dunamis offers. Cutting-Edge Technology And American Innovation Dunamis Charge's EV charging stations are engineered to exceed expectations in three critical areas: reliability, durability and charging speed. The company says its intelligent charging technology ensures consistent performance, minimizing downtime and maximizing user satisfaction. Using high-quality, weather-resistant materials, these chargers are built to last, and designed to withstand harsh environmental conditions, from extreme temperatures to severe weather events. Speed is of the essence in today's fast-paced world, and Dunamis Charge delivers. Their chargers range from 9kW to over 360kW, catering to various charging needs. This means EV owners can charge their vehicles in minutes rather than hours, potentially revolutionizing the convenience of electric vehicle ownership. Dunamis Charge’s manufacturing facility is in Detroit, a part of its commitment to offering American-made products. With the capacity to produce 200,000 EV chargers annually on a single shift, Dunamis seems well-positioned to help meet the growing demand for charging infrastructure across the United States. This strategic location not only supports local jobs but also ensures the highest quality standards in production, reports Dunamis. Scalability, Adaptability And Environmental Impact Recognizing the diverse needs of the EV market, Dunamis Charge offers a range of solutions to meet varying charging requirements across different vehicles, locations and use cases. From Level 2 AC chargers to high-power DC fast chargers, the company provides a comprehensive suite of charging solutions suitable for residential areas, commercial parking lots, multi-family dwellings and public spaces. Dunamis Charge's intelligent charging systems incorporate advanced features such as load balancing and smart energy management. These technologies optimize charging efficiency, reduce strain on the electrical grid, and lower operational costs for charging station operators. The company's commitment to upgradeable infrastructure ensures that its charging stations can evolve with rapidly advancing EV technology. Beyond providing cutting-edge technology, Dunamis Charge is helping drive sustainable change in the transportation sector. By facilitating the widespread adoption of electric vehicles, the company plays a crucial role in reducing carbon emissions. Their energy-efficient charging solutions and sustainable manufacturing practices align with a broader mission of promoting a greener future. Helping Shape The Future Of EV Charging Dunamis Charge is actively helping shape the future of electric vehicle infrastructure. The company reports being at the forefront of developing ultra-fast charging solutions, aiming to push the boundaries of charging speeds to make EV charging as quick and convenient as refueling a traditional gasoline vehicle. Looking ahead, Dunamis Charge envisions seamless integration with smart grids, enabling dynamic load management and vehicle-to-grid capabilities. The company is also exploring wireless charging technology, which could revolutionize EV charging by making it even more convenient and opening up new possibilities for infrastructure deployment. Investment Opportunity in Advanced EV Charging Technology As the EV charging station market is forecast to grow at a CAGR of 36% over 2022-2032, Dunamis Charge is all in. The company's focus on reliability, durability and speed, combined with its strategic positioning and scalable business model, sets it apart, and the company may be worth looking into for investors looking for opportunities in this growing market. As the world moves towards a more sustainable future, Dunamis Charge may be poised to play a crucial role in powering that transition. To learn more about this investment opportunity and how Dunamis Charge is shaping the future of EV charging, click here. Featured photo courtesy of Dunamis Charge. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 03, 2024 08:50 AM Eastern Daylight Time

Image
Article thumbnail News Release

Revolutionizing Trading: BullRush’s Plan To Change The Game

Benzinga

By James Blacker, Benzinga Traders eager to sharpen their skills now have the chance to do so while competing for cash prizes with a new trading platform that blends the excitement of fantasy sports with trading. With its gamified, interactive environment offering multi-asset trading competitions, trivia tournaments and other challenges, BullRush is changing the game for traders of all levels. Launched in beta on July 10, the platform has already attracted over 13,700 traders from more than 150 countries. Those participating in this testing phase can contribute to the platform’s development by exploring BullRush’s cutting-edge features, which include live market simulation, advanced strategy testing and interactive dashboards that let you monitor your performance, track rankings and analyze your competitors. Even during the beta phase, testers can win real prizes in competitions, as well as earn XP and climb the leaderboard. Participants will also be able to talk with other traders through the BullRush Discord channel, sharing strategies and getting feedback. BullRush plans to release an in-platform chat in the future to make communication even easier. The full version, which launches on September 9, will include daily, weekly and monthly trading competitions in asset classes like forex, crypto, futures and CFDs. Some of these will be free to take part in, while others will require an entry fee, with prizes depending on the entry fee and the number of participants. It will also offer free-to-enter trivia competitions, where traders can win cash prizes and XP, as well as trading challenges that give them a chance to win double the entry fee. To help traders hone their skills, the company also plans to launch BullRush Academy, which will be available to all BullRush traders. This will include a library of trading courses and videos, as well as expert trade analysis of your past trades. Traders will also have the opportunity to fine-tune their strategy in practice arenas and free-to-enter trading games. Trade, Compete, Win Trading competitions are not exactly new, with some prop firms and brokers running their own versions of them, so what makes BullRush different? The primary concern many have with most trading games is that they are single-round contests with limited rules, where the winner is the trader with the highest percentage return. What this means is that anyone could catch a lucky trade and get a huge return that wins them the game. To ensure that only the best traders win, BullRush has developed multi-round tournaments, similar to the format used in sporting events such as sports World Cups or the Olympics. In BullRush tournaments, traders progress through anywhere from 2 to 12 rounds until a winner emerges. For example, in the first BullRush competition held in July, a total of 5,246 participants were divided into four groups for the first round. After a week of trading, the top 25 traders from each group advanced to the Championship Round, where the top 100 traders competed to be crowned the first BullRush Tournament Champion. To help promote the official launch of Bullrush on September 9, the company is running a multi-asset trading competition where 100 traders will share a total prize pool of $10,000. If you think you’ve got what it takes to take home the prize, you can sign up for it here. Whether you trade FX, indices, metals or crypto, BullRush offers an excellent environment to test strategies, learn from others and enjoy the thrill of a gamified trading competition. Featured photo courtesy of BullRush. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 03, 2024 08:45 AM Eastern Daylight Time

Image
Article thumbnail News Release

Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones

Benzinga

By Anthony Termini, Benzinga In August 2020, popular actor Chadwick Boseman succumbed to colorectal cancer at the age of 43 after a four-year battle with colon cancer. The untimely death of the Black Panther star saw many fans overcome with grief but also brought attention to the danger posed by such cancers. Colorectal cancer is the second leading cause of cancer death in the United States, with more than 100,000 cases diagnosed so far in 2024. Mainz Biomed (NASDAQ: MYNZ), a German company whose U.S. offices are in Berkeley, California, believes the threat can be mitigated by technology and is working on a predictive test that may be more effective than solutions currently on the market. Benzinga recently sat down with the company’s CFO, Bill Caragol, to discuss the challenge and all the work the company is doing to help address it. The Available Options For Detecting Colorectal Cancer The standard of care for detecting colorectal cancer has since 1969 been the colonoscopy. The procedure is invasive and not very pleasant. In 2014, the fecal immunochemical test (FIT) received FDA approval. The test analyzes a person’s DNA to detect advanced adenomas, the pre-cancerous polyps that “may be the most valid…marker for present and future colorectal cancer risk,” according to research published by the National Library of Medicine. Blood-based tests are also available to detect colorectal cancer risk. However, some in the medical community are cautious about their use. According to David Lieberman, MD, chair of the American Gastroenterological Association’s Colorectal Cancer Workshop, “blood tests are neither as effective or cost-effective" as established colorectal cancer screening tests – something that Mainz’s Caragol testifies to, as well, stating that doctors continue to prescribe stool-based tests over blood tests because of the clinical differentiation since stool-based tests are better at detecting early-stage cancer, despite the “yucky factor.” He added,”Remember, [with] colorectal cancer – you detect late-stage, there’s a roughly 10% survival. When you catch it in early-stage, there’s 90% survival.” Mainz’s Breakthrough Device Leads To Next-Generation Screening Test Mainz has developed a molecular diagnostic solution to detect colon cancer risk. In July, Mainz submitted an application to the U.S. Food and Drug Administration (FDA) requesting Breakthrough Device Designation for a non-invasive colorectal cancer product that includes a portfolio of mRNA biomarkers. Studies conducted by Mainz revealed that its mRNA-powered test showed a sensitivity for detecting precancerous polyps that is double that of products currently on the market. In those studies, competitors’ tests “demonstrated efficacy of detecting advanced adenomas in the 40% range,” says Bill Caragol. Caragol added that readouts from the three clinical studies Mainz conducted between 2023 and 2024, “demonstrated consistent accuracy above 80%, a quantum leap...over the other stool-based tests.” Mainz says its flagship product, ColoAlert®, misses far fewer cases than its competitors’ tests. Mainz puts the number at up to 60% fewer cases. Its next-generation FIT test is an enhancement of ColoAlert and was submitted to the FDA in July for Breakthrough Device designation. The next-generation FIT test is complemented by a proprietary algorithm that uses artificial intelligence and machine learning to identify mRNA biomarkers in order to better detect the early warning signals of potential colorectal cancer. Mainz said the test is “a new gold standard for noninvasive detection of advanced adenomas.” The company is scheduled to conduct an FDA pre-market approval study in 2025 for its next-generation test. A focus of the study is to distribute the next-generation test kit through the currently existing network of FDA-approved national reference testing laboratories in the United States. This differs from other products currently on the market in that the companies that make those test kits also control the testing process. As Caragol describes it, “every test [is] manufactured by them, sent out by them, returned to them [for analysis], test results delivered.” As a result, says Caragol, Mainz will have “the only product that will fit into the largest distribution.” Milestones Mainz Is Focused On For The Year Ahead Mainz has a clear strategy for approaching the market. Caragol said that they realize that as a small company targeting a large market, they will have to strategically align themselves with larger companies. The company is looking to partner with a PCR provider as well as one of the national reference labs. PCR labs specialize in blood, urine and other molecular testing to detect pathogens, commonly used for diagnosing infections like COVID-19. National reference labs offer a wide range of high-accuracy diagnostic services, including PCR, serving as centralized hubs for specialized testing across various locations. Having these partnerships in place is necessary for Mainz to conduct its FDA pre-market approval study. Importantly, they will also be important allies if the company receives approval to sell the kits. They will be integral components of Mainz’s commercial go-to-market strategy. At that point, Mainz’s commercial roadmap will focus on creating partnerships and awareness within physician networks and health care professionals about the differentiating benefits of the ColoAlert mRNA powered test. Investment Drivers For Companies Like Mainz Biomed If the company can meet each of its milestones, then it could set a course for future growth. The U.S. market for colorectal screening “is over $30 billion a year,” according to Caragol. He notes that the market is double that worldwide. There are a number of companies competing domestically for colorectal screening, the most notable of which is Exact Sciences Corp. (NASDAQ: EXAS). Caragol says Exact has about a 10% share of U.S. sales. As such, there may be an opportunity for Mainz if its next-generation test receives FDA approval in the next few years. The company says that a successful launch could open the door to other products, including test kits for pancreatic and other gastrointestinal cancers – significantly expanding its addressable market. For more information about Mainz Biomed listen to the conversation Bill Caragol had with Benzinga’s Zunaid Suleman. Featured photo by Furiosa-L from Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 03, 2024 08:35 AM Eastern Daylight Time

Image
Article thumbnail News Release

AJNA BioSciences’ Strategy For Market Leadership In Botanical Drug Development With Magic Mushrooms And Cannabis

Benzinga

By Anthony Termini, Benzinga Individual investors can own equity in AJNA BioSciences on the same terms as venture capitalists and professional angels. Click here for details. Consumers are increasingly demanding natural health solutions, with recent surveys demonstrating that a majority of consumers believe products with natural ingredients are healthier and that botanical supplements are effective. Many people believe that “food should be medicine.” Littleton, Colorado-based AJNA Biosciences says it is aiming to build a bridge “between what people want, and physician advocacy they can trust.” AJNA's Pharmaceuticals Come From Nature Backed By Science AJNA is focused on developing a new class of drugs derived from botanicals. The company is exploring plant and fungi species with therapeutic compounds that address specific conditions. “The future of medicine is actually millions of years old,” says Joel Stanley, CEO of AJNA. This ethos is guiding AJNA’s development of two drug candidates focused on treating conditions that it estimates today affect more than 80 million people. The company’s research team, led by scientists from Harvard, Johns Hopkins and New York University, are working on botanical drugs to treat or support people with Autism Spectrum Disorder and Generalized Anxiety Disorder. Today, there is no FDA-approved natural remedy for either of these conditions, reports AJNA. They can both be treated with synthetic compounds engineered by big pharmaceutical companies, but those drugs can come with a number of unpleasant side effects. AJNA distinguishes itself by participating in the evolving field of botanical drug development and is pioneering a new regulatory pathway to produce drugs from plant medicine that are ultimately approved by the U.S. Food and Drug Administration (FDA). AJNA has advanced the development of two prescription drug candidates by standardizing botanical raw materials to meet strict FDA guidelines. The first drug candidate, CBD for Autism Spectrum Disorder (ASD), is preparing to enter phase 2 clinical trials with an upcoming Investigational New Drug (IND) filing, while the second candidate, Psilocybin for Generalized Anxiety Disorder (GAD), is approaching phase 1. The two drugs in development are a full-spectrum cannabis-derived drug and a psilocybin-based antidepressant. AJNA says it will look to expand indications for these products beyond autism and anxiety to also include post-traumatic stress disorder, various sleep disorders, attention-deficit/hyperactivity disorder and chronic pain. A Holistic Approach Based On Ethics And Sustainability AJNA believes it is tapping into rising consumer demand for holistic treatment options that include natural remedies. The company says that demand has never been higher. As part of the company’s ethos, it is committed to sustainable methods in its research and development processes. It is also committed to reducing its ecological footprint. AJNA follows Stanley's previous venture, a company he founded with his brothers called Charlotte’s Web Holdings (OTC: CWBHF). It started out as a mission not a company, giving away an extract to those who could benefit, then gained public recognition after the CBD oil was being used to treat seizures in 5-year-old Charlotte Figi. The company prioritizes minimizing the use of unnecessary and potentially harmful chemicals. AJNA's psilocybin drug is processed using only the water from the fungi itself, without any added agents or artificial chemicals. If this drug gains FDA approval, it could be one of the few organic options available on the market. Additionally, the company's commitment to environmental sustainability results in a largely organic waste stream, which is repurposed as compost and used as a soil amendment throughout the Denver area. AJNA Could Be Poised To Benefit From Significant Shifts In Perception The demand for psychedelic-assisted therapy is increasing at a time when the FDA is defining new drug development pathways for botanical drugs to get approved. This is helping AJNA build a bridge between what people want and the physician advocacy necessary to gain wider public trust. The company’s Chief Medical Advisor, Orrin Devinsky, is one of the first clinicians to research cannabinoids. His work as principal investigator led to the development of Epidiolex, the only FDA-approved cannabis-derived drug currently on the market. “It is important for us to provide a [botanical] option that has clinical science behind it, so doctors can get behind it, so insurance can cover it for people in the future,” said Stanley about AJNA’s research and development and pending clinical trials. AJNA also gains an advantage from unique intellectual property regulations that protect botanical drugs. Plant variety patents provide 20 years of protection, significantly longer than the five to seven years typically granted to synthetic drug compounds. Big Pharma May Look To Botanicals For Future Growth AJNA believes that major pharmaceutical and biotechnology companies will increasingly recognize the therapeutic and commercial potential of botanical drugs. Cannabinoids and psychedelics could be part of future opportunities for large players to acquire or merge with smaller botanical drug companies. This is part of an established playbook in the biotech industry. A small company’s successful drug development platform creates potential liquidity for investors. This may include the acquisition of a single drug candidate or the entire company. In many cases, these acquisitions take place before the target company begins to generate revenue. In AJNA’s case, the company is working with Wefunder to help it raise capital. Wefunder is a public benefit corporation with a goal to “fix capitalism” in addition to helping companies create shareholder value. More information is available on the Wefunder website. Featured photo courtesy of AJNA BioSciences. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 03, 2024 08:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

NAVEX Announces 2024 Excellence Awards Finalists

NAVEX Global

NAVEX, a leading provider of integrated risk and compliance management software, announces today the 2024 NAVEX Excellence Awards finalists. Now in its fourth year, the awards celebrate organizations that demonstrate exceptional commitment to corporate governance, risk mitigation, and ethical practices. Each year, the NAVEX Excellence Awards highlight how robust governance, risk and compliance (GRC) programs can strengthen corporate culture and meaningfully impact business outcomes that matter. The 2024 finalists exemplify how effective GRC initiatives can proactively manage and mitigate risks when woven into the organizational fabric. "Congratulations to this year’s nominees and finalists for their outstanding achievements," said NAVEX Chief Customer Officer, Steve Chapman. "We are proud to partner with customers who are dedicated to advancing their GRC efforts. These awards shine a spotlight on some of the most innovative and effective programs in the industry, and we applaud the compliance teams at these companies for their ongoing efforts to build highly ethical, risk-aware organizations." The winners will be honored in several categories, including Ethics & Compliance, Risk Management, and Risk and Compliance Program of the Year. Selected from a highly competitive pool of nominations, this year’s finalists include: As in previous years, the judging panel brings together a mix of NAVEX leaders and seasoned GRC professionals. This year’s esteemed panel features: Barbara Boehler, Senior Director, Program on Corporate Compliance and Ethics, Fordham Law Bill Cameron, Founder and Principal, Cameron Advisory Services Carol Williams, CEO and Enterprise Risk Management Consultant, Strategic Decision Solutions Carrie Penman, Chief Risk and Compliance Officer, NAVEX Kyle Brasseur, Former Editor in Chief, Compliance Week Kyle Martin, Vice President of GRC Solutions, NAVEX Matt Kelly, Editor and CEO, Radical Compliance LLC Stephen Chapman, Chief Customer Officer, NAVEX Vera Cherepanova, Ethics Advocate, Consultant, Author, Studio Etica Award recipients will be announced after to the 2024 NAVEX Next Virtual Conference on October 1. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global +1 617-388-5773 scott.levesque@navex.com Company Website https://navex.com

September 03, 2024 08:06 AM Eastern Daylight Time

1 ... 2223242526 ... 3725